DESCRIPTION
Cancer detection methods traditionally rely on invasive procedures or single-marker assays that often yield false positives. This technology introduces a novel method for identifying tumor-derived extracellular vesicles (EVs) through antibody binding and beta-sheet structure analysis.
The process involves:
- Combining an antibody with a sample to form antigen-antibody complexes specific to tumor-derived EVs
- Exposing these EVs to a compound that binds to beta-sheet structures
- Assessing changes in binding to determine the presence of cancerous cells
Benefits
- Noninvasive and minimally invasive cancer detection
- High specificity and sensitivity in identifying cancerous EVs
- Compatible with existing diagnostic and prognostic biomarkers to improve overall performance
Applications
- Early Cancer Diagnosis
- Disease Progression Monitoring and Treatment Response
- Screening Option for High-Risk Populations
Patent
This technology has a U.S. Patent 2022/0349891 A1 pending and is available for licensing/partnering opportunities.
